VIA EDGAR
June 29, 2017
| Re: | Proteostasis Therapeutics, Inc. |
Registration Statement on Form S-3
(FileNo. 333-218545)
SECURITIES AND EXCHANGE COMMISSION
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Ladies and Gentlemen:
Pursuant to Rule 461 under the Securities Act of 1933, as amended, Proteostasis Therapeutics, Inc. hereby requests that the effective date of the above-referenced Registration Statement be accelerated so that it may become effective at 4:00 p.m., Washington, D.C. time, on July 3, 2017, or as soon as possible thereafter.
Once the Registration Statement has been declared effective, please orally confirm that event with our counsel, Goodwin Procter LLP, by calling Sarah Ashfaq, Esq., at (212)459-7238.
| Very truly yours, | ||||
| PROTEOSTASIS THERAPEUTICS, INC. | ||||
| By: | /s/ Meenu Chhabra | |||
| Name: | Meenu Chhabra | |||
| Title: | Chief Executive Officer | |||
| cc: | Jeff Held,Proteostasis Therapeutics, Inc. |
Mitchell S. Bloom,Goodwin Procter LLP
John Mutkoski,Goodwin Procter LLP